{"entity":{"id":"nct07227350","kind":"trial","name":"L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)","aka":[],"tldr":"A phase 2 trial of L19IL2 in basal cell carcinoma, run by Philogen S.p.A., now recruiting.","summary":"L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC) is a phase 2 interventional study registered as NCT07227350 by Philogen S.p.A., with 180 participants planned, started 2026-06-01 and due to reach its primary completion in 2031-02. Interventions recorded: L19IL2, L19TNF and L19IL2/L19TNF.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07227350","url":"https://clinicaltrials.gov/study/NCT07227350"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["basal-cell-carcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["philogen-s-p-a"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07227350","phase":"2","setting":"A Phase 2 Controlled Randomized Study of the Efficacy of L19IL2 or L19TNF or L19IL2/L19TNF Intralesional Injections for the Treatment of Locally Advanced Basal Cell Carcinoma (LaBCC)","sponsor":"Philogen S.p.A.","enrolled":180,"outcomes":[]},"route":"/trials/nct07227350/","neighbours":{"cancer":[{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/"}],"company":[{"id":"philogen-s-p-a","kind":"company","name":"Philogen S.p.A.","route":"/companies/philogen-s-p-a/"}]}}